GoAI
Get started
InspireMD, Inc. logo

InspireMD, Inc.

NSPR

NASDAQHealthcareMedical - Devices

Open in GoAI

Previous close

$0.8998

−$0.0001 · -0.01%

Aug 21, 4:00 PM ET

NSPR company overview

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

67

Undervalued

Momentum

17

Strong Down

Sentiment

68

Bullish

Risk resilience

31

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

InspireMD, Inc., an Israel-based medical technology company established in 2005, specializes in creating and commercializing advanced medical devices. Its core expertise lies in the proprietary MicroNet stent platform technology, engineered to address various vascular and coronary diseases. The company's offerings, distributed through a network of local partners, reach markets across Europe, Latin America, the Middle East, and Asia Pacific. Key products include the CGuard carotid embolic prevention system, specifically designed for carotid artery procedures, and the MGuard Prime embolic protection systems. The MGuard Prime systems are crucial for patients experiencing acute coronary syndromes, notably acute myocardial infarction, and those undergoing saphenous vein graft coronary interventions or bypass surgery. InspireMD is also developing PVGuard, an innovative solution combining a MicroNet mesh sleeve with a self-expandable stent, aimed at peripheral vascular applications.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
US
CEO
Marvin L. Slosman
Listed since
Apr 12, 2011
Employees
127

Market position

Day range

Current $0.8998

52-week range

Current $0.8998

Open
$0.8906
Previous close
$0.8999
Volume
83.91K
0.49× average
Average volume
169.58K
Average daily volume
Market cap
42.15M USD
Beta
0.77
Market reference 1
50-day average
$0.7394
+21.69% above average
200-day average
$1.3743
-34.52% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
125.12M USD
EV / EBITDA
-2.59×
Earnings yield
-37.31%
Free cash flow yield
-28.11%

Profitability & efficiency

Return on equity
-88.38%
Return on assets
-70.29%
Return on invested capital
-82.18%

Financial health

Current ratio
5.74×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends87%-143%-374%-605%Gross margin, FY2021: 16.77%Gross margin, FY2022: 21.60%Gross margin, FY2023: 29.12%Gross margin, FY2024: 21.49%Gross margin, FY2025: 29.50%Operating margin, FY2021: -327.39%Operating margin, FY2022: -361.88%Operating margin, FY2023: -340.74%Operating margin, FY2024: -478.00%Operating margin, FY2025: -546.97%Net margin, FY2021: -331.88%Net margin, FY2022: -357.59%Net margin, FY2023: -320.97%Net margin, FY2024: -456.63%Net margin, FY2025: -543.33%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 16.77%. Gross margin FY2022 21.60%. Gross margin FY2023 29.12%. Gross margin FY2024 21.49%. Gross margin FY2025 29.50%. Operating margin FY2021 -327.39%. Operating margin FY2022 -361.88%. Operating margin FY2023 -340.74%. Operating margin FY2024 -478.00%. Operating margin FY2025 -546.97%. Net margin FY2021 -331.88%. Net margin FY2022 -357.59%. Net margin FY2023 -320.97%. Net margin FY2024 -456.63%. Net margin FY2025 -543.33%.

Income trends

Revenue

8.98M USD+28.11%

Operating income

−49.11M USD-46.59%

Net income

−48.79M USD-52.43%
Income trends across reported periods14.79M USD−8.45M USD−31.68M USD−54.92M USDRevenue, FY2021: 4.5M USDRevenue, FY2022: 5.17M USDRevenue, FY2023: 6.21M USDRevenue, FY2024: 7.01M USDRevenue, FY2025: 8.98M USDOperating income, FY2021: −14.72M USDOperating income, FY2022: −18.71M USDOperating income, FY2023: −21.14M USDOperating income, FY2024: −33.5M USDOperating income, FY2025: −49.11M USDNet income, FY2021: −14.92M USDNet income, FY2022: −18.49M USDNet income, FY2023: −19.92M USDNet income, FY2024: −32.01M USDNet income, FY2025: −48.79M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 4.5M USD. Revenue FY2022 5.17M USD. Revenue FY2023 6.21M USD. Revenue FY2024 7.01M USD. Revenue FY2025 8.98M USD. Operating income FY2021 −14.72M USD. Operating income FY2022 −18.71M USD. Operating income FY2023 −21.14M USD. Operating income FY2024 −33.5M USD. Operating income FY2025 −49.11M USD. Net income FY2021 −14.92M USD. Net income FY2022 −18.49M USD. Net income FY2023 −19.92M USD. Net income FY2024 −32.01M USD. Net income FY2025 −48.79M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue8.98M USD7.01M USD6.21M USD5.17M USD4.5M USD
Cost of goods sold6.33M USD5.5M USD4.4M USD4.05M USD3.74M USD
Gross profit2.65M USD1.51M USD1.81M USD1.12M USD754K USD
Research and development15M USD13.63M USD7.98M USD7.81M USD5.16M USD
Selling, general, and administrative37.26M USD21.38M USD14.97M USD12.02M USD10.31M USD
Operating expenses51.76M USD35.01M USD22.95M USD19.83M USD15.47M USD
Interest income—1.56M USD1.29M USD250K USD—
Interest expense————157K USD
Depreciation and amortization476K USD280K USD232K USD188K USD161K USD
Operating income−49.11M USD−33.5M USD−21.14M USD−18.71M USD−14.72M USD
Net income−48.79M USD−32.01M USD−19.92M USD−18.49M USD−14.92M USD

Company facts updated Aug 24, 2026.

Earnings

Latest fiscal-year EPS
-0.76
FY2025
Latest fiscal-year revenue
8.98M USD
FY2025 · +28.11% year over year

Annual EPS trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual EPS trend-0.6-1.24-1.87-2.51FY21FY22FY23FY24FY25

Annual revenue trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual revenue trend9.43M7.63M5.84M4.05MFY21FY22FY23FY24FY25

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$4.00

344.54% upside
Past 12 months12-month forecast

Price history unavailable

High $5.00Average $4.00Low $3.00

Rating distribution

7 ratings
Strong buy00%
Buy686%
Hold114%
Sell00%
Strong sell00%

Recent analyst actions

1 institution

NSPR news

zacks.com

InspireMD (NSPR) Upgraded to Buy: Here's What You Should Know

InspireMD (NSPR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Read source
seekingalpha.com

InspireMD, Inc. (NSPR) Q2 2026 Earnings Call Transcript

InspireMD, Inc. (NSPR) Q2 2026 Earnings Call Transcript

Read source
globenewswire.com

InspireMD Reports Second Quarter 2026 Financial Results

- Company to host investor conference call today, August 17 th , at 8:30am EDT - MIAMI, Aug. 17, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime…

Read source
zacks.com

InspireMD, Inc. (NSPR) Reports Q2 Loss, Beats Revenue Estimates

InspireMD, Inc. (NSPR) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.2. This compares to a loss of $0.26 per share a year ago.

Read source
globenewswire.com

InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MIAMI, Aug. 07, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the…

Read source
globenewswire.com

InspireMD Appoints Carotid Intervention Commercial Leader Kathleen Kennedy as Senior Vice President of Global Sales and Marketing

Ms. Kennedy returns to InspireMD having previously served as Sales Director supporting the initial U.S. launch of CGuard Prime Ms. Kennedy returns to InspireMD having previously served as Sales Director supporting the…

Read source

Corporate actions

Corporate action history

Stock split

Effective Apr 27, 2021

1:15

Stock split

Effective Apr 1, 2019

1:50

Stock split

Effective Feb 8, 2018

1:35

Stock split

Effective Oct 10, 2016

1:25

Stock split

Effective Oct 1, 2015

1:10

Stock split

Effective Dec 21, 2012

1:4

NSPR peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding NSPR

Funds reporting this stock among their holdings, ordered by reported position size.

iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
104.7K
Weight
0.01%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%

Continue in GoAI

Research NSPR

research.disclaimer